This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

  • Home
  • Published Projects
  • Registries
Advanced Search

Study Preview



Study Title and Description

Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.



Key Questions Addressed
2 KQ2a. What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, triptans, ergots alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid pharmacologic treatments, such as those in a different medication class; or 2) nonpharmacologic therapy for outcomes related to pain, function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? KQ2b. How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication; (4) dose of medication; (5) duration of treatment? KQ2c. What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1) misuse, (2) overdose; (3) MOH, (4) other harms including gastrointestinal-related harms, cardiovascular-related harms, kidney-related harms, falls, fractures, motor vehicle accidents, endocrinological harms, infections, cognitive harms, and psychological harms (e.g. depression)? KQ2d. How do harms vary depending on: (1) patient demographics (e.g. age, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication; (4) dose of medication; (5) the duration of therapy?
  • Comments Comments (
    0
    ) |
  • Post/View

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.
Author Ho TW., Ho AP., Chaitman BR., Johnson C., Mathew NT., Kost J., Fan X., Aurora SK., Brandes JL., Fei K., Beebe L., Lines C., Krucoff MW.
Country Merck Sharp & Dohme Corp., Whitehouse Station, NJ 19454-1099, USA. tony.ho@merck.com
Year 2012
Numbers Pubmed ID: 22221076

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Question 2
Design Details
Question... Follow Up Answer Follow-up Answer




Results & Comparisons

No Results found.